Roseola Infantum (exanthum subitum, sixth disease)
Roseola Infantum (exanthum subitum, sixth disease) ICD-9 058.10
Are You Confident of the Diagnosis?
What you should be alert for in the history
Roseola infamtum is a common infectious disease of infancy characterized by a rash proceeded for 3-5 days by high fever (40-40.5°C; 104-105°F) in an otherwise healthy appearing infant.
Characteristic findings on physical examination
These include rose pink macules and papules on the trunk, neck, extremities, and less commonly on the face. Upper respiratory findings such as injection of the tympanic membranes, in addition to cervical or occipital lymphadenopathy may be appreciated. Red papules on the soft palate may be seen (Nagayama’s spots), as well as uvulo-palatoglossal junction ulcers. Bulging fontanelles, seizures, encephalopathy, or aseptic meningitis may alert the practitioner to neurological involvement
Expected results of diagnostic studies
Laboratory investigations for diagnosing human herpesvirus (HHV) include serologies, antigen detection, PCR, and immunofluorescence.
Differential diagnoses include other viral exanthems such as adenovirus, enterovirus, parvovirus B19, rubella, and parainfluenza.
Who is at Risk for Developing this Disease?
Infants and toddlers between 6 months and 3 years of age are the highest risk group with the peak age being 6-7 months. It is more common in the spring.
What is the Cause of the Disease?
HHV-6 and HHV-7. HHV-6 and HHV-7 is acquired via respiratory droplet. The virus replicates in T cells, although widespread infection is possible. Viremia occurs 2 days prior to the onset of fever, and is self-limiting. Latency is established and most commonly occurs in the salivary glands and peripheral blood mononuclear cells.
Systemic Implications and Complications
Patients with HIV or immunosuppressed patients may experience reactivation of the virus. The non-specific features of fever, malaise, and rash may mimic acute graft-versus-host disease. Bone marrow failure, neurological involvement, or pneumonitis may ensue. Since HHV-6 has several genes which transactivate long terminal repeat (LTR) of HIV, it is proposed that HHV-6 may have a role as the cofactor for AIDS.
In most cases the disease is mild and self-limiting, and treatment is supportive using antipyretics, such as acetaminophen during the febrile stage. In more severe cases, ganciclovir or foscarnet have activity against HHV-6 and HHV-7. The virus is less responsive to acyclovir.
Optimal Therapeutic Approach for this Disease
Use anti-virals as above in severe disease, and control fever with anti-pyretics as needed.
The otherwise healthy infant can be managed as an outpatient. At the onset of the rash, the fever should improve, with the rash resolving in 5-10 days.
In a patient with neurological symptoms, inpatient monitoring is necessary, and initiation of anti-virals should be strongly considered.
Unusual Clinical Scenarios to Consider in Patient Management
Intractable seizures following roseola have been reported.
HHV-6 has been implicated as an etiologic agent in drug hypersensitivity syndomes, with ganciclovir being used therapeutically
What is the Evidence?
Torigoe, S, Kumamoto, T, Koide, W, Taya, K, Yamanishi, K. "Clinical manifestations associated with human herpesvirus 7 infection". Arch Dis Child. vol. 72. 1995 June. pp. 518-519.(Documents association of herpes virus with clinical manifestations of roseola.)
Dyer, JA. "Childhood Viral Exanthems". Pediatr Ann. vol. 36. 2007 Jan. pp. 21-9.(Provides clincal overview of childhood exanthems including roseola.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers